NFKB1 and MALT lymphoma: Two important immunomodulatory drugs, or “IMiDs,” thalidomide and lenalidomide, have been evaluated for efficacy in certain subgroups of hematological malignancies, including MALT lymphoma, since they have a targeting effect on NF-κB signaling [25,112,122,123].